RMC No. 47-2022: Publishes the full text of the letter from the Food and Drug Administration of the DOH endorsing updates to the List of VAT-Exempt Medicines under RA No. 11534 (CREATE Act)

Files
Download this file

Summary

RMC No. 47-2022 publishes the full text of the March 29, 2022 letter from the Food and Drug Administration (FDA) of the DOH endorsing updates to the List of VAT-Exempt Medicines under RA No. 11534 (CREATE Act).

CollapseExpand

Key points

  1. Letter published. The letter is from Dr. Oscar G. Gutierrez, Jr., OIC-Director General of the FDA. It asks for the inclusion of certain medicines for COVID-19 treatment in the List of VAT-Exempt Medicines.
  2. Directive. Internal revenue officers and others concerned are to be guided accordingly and give the Circular wide publicity.

Who is affected

  • Internal revenue officers and others concerned

Summary by Tax Resources PH. It is not a substitute for the full text of the issuance or professional advice.

Copies of BIR issuances are hosted here for reference. For the official version, check bir.gov.ph. Summaries by Tax Resources PH are not a substitute for the full text or professional advice.